Yerson Alberca-Naira

Dr. Yerson Alberca-Naira

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2025 in Public Health
Verified
Journal Article
Closed access
NFNoha Fadl
Noha Fadl
AGAssem Gebreal
Assem Gebreal
SAShaimaa Abdelaziz Abdelmoneim
Shaimaa Abdelaziz Abdelmoneim
FAFatima Asim Abdelmoneim
Fatima Asim Abdelmoneim
MJMaryam Khalil E. Jasim
Maryam Khalil E. Jasim
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy

21 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BTBryam López Tuesta
Bryam López Tuesta
CSCAMILA ARTET ARONES SANTAYANA
CAMILA ARTET ARONES SANTAYANA
GSGustavo Alonso Valderrama Saenz
Gustavo Alonso Valderrama Saenz
Yerson Alberca-NairaYerson Alberca-Naira
Yerson Alberca-Naira
HTHector I. Cedillo Torres
Hector I. Cedillo Torres
JBJoshuan J. Barboza
Joshuan J. Barboza
Introduction: Impetigo is a relatively common superficial infection of the skin and soft tissues. Although its prevalence is more significant in childhood, it might also occur in adulthood, affecting the quality of life of our patients. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ozenoxacin 1% with placebo or mupirocin was conducted. Databases searched included PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model, and heterogeneity was assessed using I2 statistics. Results: Four RCTs with 754 patients met the inclusion criteria. Ozenoxacin significantly improved the clinical success (RR: 1.14, 95% CI: 1.04–1.26, and I2 = 0%) and reduced the clinical failure (RR: 0.54, 95% CI: 0.39–0.75, and I2 = 0%) compared to the placebo. Microbiological success was also superior (RR: 1.31, 95% CI: 1.05–1.58, and I2 = 4%), while the microbiological failure was significantly lower (RR: 0.31, 95% CI: 0.21–0.46, and I2 = 0%). Comparisons with mupirocin showed similar efficacy, though the estimates were less precise. Conclusions: Ozenoxacin 1% is an effective treatment for impetigo, significantly improving clinical and microbiological outcomes while reducing the failure rates compared to the placebo. Its efficacy is comparable to mupirocin, suggesting it as a viable alternative for first-line therapy. Given the low heterogeneity observed, these findings support the clinical use of ozenoxacin for impetigo management. Future large-scale RCTs and direct comparative studies are warranted to further validate its therapeutic benefits.

Verified
Journal Article
Open access
PDF file
BTBryam López Tuesta
Bryam López Tuesta
Yerson Alberca-NairaYerson Alberca-Naira
Yerson Alberca-Naira
JLJhair Alexander Leon-Rodriguez
Jhair Alexander Leon-Rodriguez
JPJonathan Javier Rodriguez Pratto
Jonathan Javier Rodriguez Pratto
Jose Daniel Andrade-SaavedraJose Daniel Andrade-Saavedra
Jose Daniel Andrade-Saavedra
JBJoshuan J. Barboza
Joshuan J. Barboza
Background/Objectives: Postoperative atrial fibrillation (POAF) is a frequent complication after cardiac surgery and is associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Numerous multivariable prediction models have been developed to estimate individual risk; however, their methodological robustness, validation status, and clinical transportability remain uncertain. This systematic review aimed to critically evaluate the methodological quality, validation strategies, and predictive performance of multivariable prediction models developed to estimate the risk of postoperative atrial fibrillation (POAF) after cardiac surgery. Methods: In accordance with PRISMA 2020 guidelines, we conducted a comprehensive search of PubMed, Scopus, Web of Science, and Embase from inception to July 2025. Studies that developed or externally validated multivariable prediction models for POAF in adult patients undergoing cardiac surgery were eligible. Data extraction was performed using the CHARMS checklist, and methodological quality was assessed with PROBAST. Model performance was summarized descriptively, focusing on discrimination (C-statistic/AUC), calibration reporting, and validation strategies. Results: A total of 39 studies were included. Most models were based on logistic regression, whereas a minority employed Cox regression or machine learning techniques. Reported discrimination ranged from 0.60 to 0.98, demonstrating substantial heterogeneity in predictive performance. Calibration was inconsistently reported. Six studies performed external validation. According to PROBAST, 32 of 39 studies (82%) were rated at high risk of bias, predominantly within the analysis domain due to inadequate handling of overfitting, insufficient events-per-variable ratios, and limited validation procedures. Conclusions: Existing prediction models for POAF show variable discrimination but are frequently limited by high risk of bias, inadequate validation, and incomplete calibration assessment, thereby restricting their clinical applicability. Future research should prioritize rigorous external validation, transparent reporting in accordance with TRIPOD recommendations, and methodological strategies that enhance model generalizability and transportability across diverse surgical populations.

28 November 2025 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
WRWagner Rios-Garcia
Wagner Rios-Garcia
SSSashenka Silva-Jiménez
Sashenka Silva-Jiménez
DBDaniel Banegas-Báez
Daniel Banegas-Báez
Yerson Alberca-NairaYerson Alberca-Naira
Yerson Alberca-Naira
JOJulissa Orbe-Ortiz
Julissa Orbe-Ortiz
ARAlondra A. Rios-Garcia
Alondra A. Rios-Garcia